Sergio Cifuentes/X
Jun 3, 2025, 13:46
Sergio Cifuentes: DB-09 continues to demonstrate superiority in all treatment settings for HER2-positive MBC
Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, shared on X:
“DB-09 continues to demonstrate superiority in all treatment settings for HER2-positive MBC.
For us oncologists in Latin America, the question is: Is this first line of treatment necessary for everyone?
The answer remains to be resolved, but I think NO!
PATINA is a study that optimizes the first line of treatment for these patients.
The opportunity to use Liquid Biopsy and ctDNA will be a valuable opportunity to research.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 4, 2025, 16:33
Jun 4, 2025, 16:33
Jun 4, 2025, 15:56
Jun 4, 2025, 14:21
Jun 4, 2025, 13:42